Prologue Medicines bolsters its executive and board leadership, naming Stephen Harrison as CSO while welcoming new directors Jason Silvers and Adrian Rawcliffe to the Cambridge-based biotech firm.
Prologue Medicines announced the appointment of Stephen Harrison as Chief Scientific Officer, a leadership addition that does not directly affect financials.
Flagship Pioneering is mentioned as the firm of Adrian Rawcliffe, who joined Prologue Medicines' board, but no direct impact.
Etiome is mentioned as the company led by Adrian Rawcliffe, who joined Prologue Medicines' board, but no direct impact.
Prologue Medicines strengthens its leadership team with the appointment of Stephen Harrison as Chief Scientific Officer. The biotechnology firm also expanded its Board of Directors, adding industry veterans Jason Silvers and Adrian Rawcliffe to support its ongoing research initiatives.
The board now includes Jason Silvers, President and CFO of Generate Biomedicines, and Adrian Rawcliffe, CEO-Partner at Flagship Pioneering and CEO of Etiome.